Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCYC NASDAQ:CLNN NASDAQ:IMRX NASDAQ:NMRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCYCBicycle Therapeutics$3.87-7.0%$4.24$3.87▼$9.16$290.42M1.55367,941 shs571,996 shsCLNNClene$5.39-1.6%$6.05$3.25▼$13.50$70.03M0.9260,638 shs48,256 shsIMRXImmuneering$4.32-1.6%$4.75$2.90▼$10.08$284.02M0.411.34 million shs465,240 shsNMRANeumora Therapeutics$1.49-4.5%$1.65$0.83▼$3.65$289.04M2.741.59 million shs665,727 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCYCBicycle Therapeutics-1.19%-0.48%+4.00%-14.05%-52.24%CLNNClene-5.84%-3.69%-5.03%-7.28%+46.52%IMRXImmuneering-1.79%-8.16%-3.30%-27.32%+7.07%NMRANeumora Therapeutics+1.30%-2.50%-3.11%-30.67%-15.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCYCBicycle Therapeutics$3.87-7.0%$4.24$3.87▼$9.16$290.42M1.55367,941 shs571,996 shsCLNNClene$5.39-1.6%$6.05$3.25▼$13.50$70.03M0.9260,638 shs48,256 shsIMRXImmuneering$4.32-1.6%$4.75$2.90▼$10.08$284.02M0.411.34 million shs465,240 shsNMRANeumora Therapeutics$1.49-4.5%$1.65$0.83▼$3.65$289.04M2.741.59 million shs665,727 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCYCBicycle Therapeutics-1.19%-0.48%+4.00%-14.05%-52.24%CLNNClene-5.84%-3.69%-5.03%-7.28%+46.52%IMRXImmuneering-1.79%-8.16%-3.30%-27.32%+7.07%NMRANeumora Therapeutics+1.30%-2.50%-3.11%-30.67%-15.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCYCBicycle Therapeutics 2.44Hold$14.00261.76% UpsideCLNNClene 2.71Moderate Buy$33.25516.88% UpsideIMRXImmuneering 2.86Moderate Buy$17.57306.75% UpsideNMRANeumora Therapeutics 2.60Moderate Buy$6.57341.04% UpsideCurrent Analyst Ratings BreakdownLatest CLNN, IMRX, NMRA, and BCYC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/20/2026IMRXImmuneering Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$11.00 ➝ $18.007/17/2026NMRANeumora Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/15/2026CLNNClene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/13/2026NMRANeumora Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$7.00 ➝ $5.007/8/2026BCYCBicycle Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/8/2026IMRXImmuneering Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$17.007/8/2026IMRXImmuneering Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$17.007/8/2026IMRXImmuneering Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$17.006/26/2026CLNNClene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/24/2026IMRXImmuneering Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/18/2026NMRANeumora Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$6.00 ➝ $4.00(Data available from 7/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCYCBicycle Therapeutics$72.86M3.71N/AN/A$8.79 per share0.44CLNNClene$200K344.42N/AN/A($1.62) per share-3.33IMRXImmuneeringN/AN/AN/AN/A$3.38 per shareN/ANMRANeumora TherapeuticsN/AN/AN/AN/A$0.62 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCYCBicycle Therapeutics-$218.96M-$3.15N/AN/AN/A-344.95%-35.74%-29.54%8/14/2026 (Estimated)CLNNClene-$26.17M-$3.20N/AN/AN/A-25,009.70%N/A-137.98%8/13/2026 (Estimated)IMRXImmuneering-$56.03M-$1.17N/AN/AN/AN/A-31.93%-29.92%8/12/2026 (Estimated)NMRANeumora Therapeutics-$236.93M-$1.33N/AN/AN/AN/A-181.70%-119.15%8/5/2026 (Estimated)Latest CLNN, IMRX, NMRA, and BCYC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2026Q2 2026BCYCBicycle Therapeutics-$0.5640N/AN/AN/A$4.77 millionN/A8/13/2026Q2 2026CLNNClene-$0.37N/AN/AN/A$0.06 millionN/A8/12/2026Q2 2026IMRXImmuneering-$0.26N/AN/AN/AN/AN/A8/5/2026Q2 2026NMRANeumora Therapeutics-$0.23N/AN/AN/AN/AN/A5/15/2026Q1 2026IMRXImmuneering-$0.30-$0.21+$0.09-$0.21N/AN/A5/14/2026Q1 2026CLNNClene-$0.6367-$0.69-$0.0533-$0.69$0.05 million$0.02 million5/7/2026Q1 2026NMRANeumora Therapeutics-$0.32-$0.30+$0.02-$0.30N/AN/A4/30/2026Q1 2026BCYCBicycle Therapeutics-$0.6209-$0.87-$0.2491-$0.87$7.50 million$0.89 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCYCBicycle TherapeuticsN/AN/AN/AN/AN/ACLNNCleneN/AN/AN/AN/AN/AIMRXImmuneeringN/AN/AN/AN/AN/ANMRANeumora TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCYCBicycle TherapeuticsN/A12.6612.66CLNNCleneN/A1.941.93IMRXImmuneeringN/A32.4532.45NMRANeumora Therapeutics0.755.095.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCYCBicycle Therapeutics86.15%CLNNClene23.28%IMRXImmuneering67.65%NMRANeumora Therapeutics47.65%Insider OwnershipCompanyInsider OwnershipBCYCBicycle Therapeutics22.00%CLNNClene28.30%IMRXImmuneering22.90%NMRANeumora Therapeutics26.94%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCYCBicycle Therapeutics24069.81 million54.45 millionOptionableCLNNClene10012.78 million9.16 millionNo DataIMRXImmuneering6064.70 million49.88 millionNot OptionableNMRANeumora Therapeutics108185.28 million135.37 millionOptionableCLNN, IMRX, NMRA, and BCYC HeadlinesRecent News About These CompaniesSiren L.L.C. Buys 2,209,039 Shares of Neumora Therapeutics, Inc. $NMRAJuly 24 at 6:25 AM | marketbeat.comStock Traders Buy Large Volume of Put Options on Neumora Therapeutics (NASDAQ:NMRA)July 18, 2026 | americanbankingnews.comNeumora Therapeutics Target of Unusually Large Options Trading (NASDAQ:NMRA)July 16, 2026 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Price Target Cut to $5.00 by Analysts at Royal Bank Of CanadaJuly 13, 2026 | marketbeat.comNeumora Therapeutics (NMRA) Stock Sees Fair Value Falls After Navacaprant DiscontinuationJuly 11, 2026 | finance.yahoo.comWhy Neumora Therapeutics, Inc. (NMRA) Is One of the Best Get Rich Quick Stocks to BuyJuly 7, 2026 | finance.yahoo.comWhy Neumora Therapeutics, Inc.’s (NMRA) Stock Is Down 9.94%June 18, 2026 | aaii.comANMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities FraudJune 18, 2026 | businesswire.comWhy Neumora Therapeutics (NMRA) Faces a Major Catalyst From Navacaprant’s Upcoming Depression DataJune 17, 2026 | insidermonkey.comThree pivotal MDD trial failures for Neumora lead to staffing cutsJune 17, 2026 | finance.yahoo.comNeumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)June 16, 2026 | prnewswire.comNeumora Stock Plunges 49% After Late-Stage Depression Drug FailureJune 16, 2026 | zacks.comNeumora bins depression drug after Phase III failuresJune 16, 2026 | thepharmaletter.comTNeumora to lay off 35% of staff after navacaprant goes 0 for 3 in late-stage depression studiesJune 15, 2026 | fiercebiotech.comFNMRA stock on track for worst day in 1.5 years — Neumora Therapeutics' lead depression drug fails late stage trialsJune 15, 2026 | msn.comPenny Stock Neumora Therapeutics Cuts Workforce After Depression Trials FailJune 15, 2026 | benzinga.comNMRA INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Neumora Therapeutics, Inc.June 15, 2026 | globenewswire.comNeumora Therapeutics scraps depression drug after two late-stage trial failuresJune 15, 2026 | reuters.comNeumora ends depression drug programme and announces workforce reduction (NMRA)June 15, 2026 | msn.comNeumora Ends Navacaprant After Phase 3 Trial FailureJune 15, 2026 | tipranks.comNeumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline UpdateJune 15, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLNN, IMRX, NMRA, and BCYC Company DescriptionsBicycle Therapeutics NASDAQ:BCYC$3.87 -0.29 (-6.97%) Closing price 04:00 PM EasternExtended Trading$3.88 +0.00 (+0.13%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.Clene NASDAQ:CLNN$5.39 -0.09 (-1.64%) Closing price 04:00 PM EasternExtended Trading$5.38 -0.01 (-0.19%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Immuneering NASDAQ:IMRX$4.32 -0.07 (-1.59%) Closing price 04:00 PM EasternExtended Trading$4.32 +0.00 (+0.12%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.Neumora Therapeutics NASDAQ:NMRA$1.49 -0.07 (-4.49%) Closing price 04:00 PM EasternExtended Trading$1.49 0.00 (0.00%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Plugging In: How Kinder Morgan Powers Up Profits TSMC’s Price Hikes Could Show Which AI Chip Stocks Have Real Pricing Power AMD’s $5 Billion Anthropic Deal Could Redraw the AI Chip Battle Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
